logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Lühua Wang

Chinese Academy of Sciences
H指数:49
被引数:8,390

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

PACIFIC-5: 在不可切除的III期NSCLC患者中巩固durvalumab的III期临床试验，同时或序贯放化疗后无进展

Journal of Hematology & Oncology
IF40.4
2025-12-070
OAAI
Yi-Long Wu; Lin Wu; Nan Bi; Timucin Cil; Hong Ge; Zhengfei Zhu; Chih-Liang Wang; Wei Zhang; Dongqing Lv; E. Mingyan; Jianguo Sun; Yi Pan; Maciej Krzakowski; Mustafa Dikilitas; Mehmet Ali Nahit Sendur; Young-Chul Kim; Yanjiao Yang; Rui Mao; Biao Zhang; Luhua Wang
Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study

比较免疫化疗联合或不联合放射治疗局限于非区域淋巴结转移的IVB期食管鳞状细胞癌的疗效：一项多中心倾向性评分匹配研究

Cancer Immunology, Immunotherapy
IF0
2025-11-180
OAAI
Qi Liu; Junqiang Chen; Yuanji Xu; Wenbin Shen; Jinjun Ye; Honglei Luo; Xizhi Zhang; Wenyang Liu; Yujin Xu; Yingying Zhang; Anwen Liu; Xiaopeng Li; Hong Ge; Qifeng Wang; Hui Luo; Lina Zhao; Conghua Xie; Qin Lin; Congying Xie; Jianping Xiong; Weiwei Chen; Luhua Wang; Kuaile Zhao
Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial

吡非尼酮治疗2级和3级放射性肺损伤：一项多中心、开放标签、随机、二期试验

The Lancet Oncology
IF0
2025-11-060
PRE
Zan Hou; Baiqiang Dong; Qiwei Yao; Hualin Chen; Qiuju Shao; Minying Li; Jianyang Wang; Keying Chen; Zhengfei Zhu; Fang Peng; Shihong Wei; Xiao Hu; Jiancheng Li; Meilian Liu; Bin Xu; Siming Zheng; Nan Bi; Shuohan Zheng; Qingqing Xu; Biqi Chen; Chenfei Wu; Rui Li; Wei Chen; Xin Liu; Yuchen Tian; Xuan Li; Suping Guo; Lei Zhao; Yujia Zhu; Ling Cai; Qiaoqiao Li; Li Li; Huilan Zhang; Chen Hu; Luhua Wang; Qiwen Li; Baoqing Chen; Ming Chen
Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients

循环肿瘤DNA为局限期小细胞肺癌患者的巩固性免疫治疗提供优化方案

Signal Transduction and Targeted Therapy
IF52.7
2025-10-160
OA
Yin Yang; Yuqi Wu; Jingjing Zhao; Tao Zhang; Kailun Fei; Xiaotian Zhao; Lei Deng; Zhihui Zhang; Ying Jiang; Jianyang Wang; Wenyang Liu; Xin Wang; Song Wang; Hua Bao; Xue Wu; Minyi Zhu; Qiuxiang Ou; Wei Tang; Luhua Wang; Zhijie Wang; Nan Bi
Long-term outcomes of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy (PORT-C): a single-centre, randomized, phase 3 trial

术后放疗对完全切除并接受辅助化疗的pIIIA-N2非小细胞肺癌患者长期结局的影响（PORT-C）：一项单中心、随机、III期试验

eClinicalMedicine
IF10
2025-10-160
OAAI
Yu Men; Yongxing Bao; Nan Bi; Zongmei Zhou; Jun Liang; Jima Lv; Qinfu Feng; Zefen Xiao; Yan Wang; Junling Li; Jie Wang; Shugeng Gao; Jie He; Zhouguang Hui; Luhua Wang
Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese study

具有罕见EGFR突变的无法切除的局部晚期肺腺癌的临床特征和预后: 一项回顾性多中心中国研究

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-01-010
OAAI
Xu, Kunpeng; Zheng, Xiao-Li; Chen, Ming; Mingyan, E.; Zhang, Li; Cao, Jianzhong; Zhang, Xu; Ding, Xiao; Xia, Bing; Zhao, Lujun; Wang, Hongbin; Li, Jiancheng; Hu, Chen; Jiang, Wei; Ge, Hong; Bi, Nan; Wang, Luhua

研究方向

暂未获取到该数据
N
Nan Bi
H 指数:36论文数:427被引数:5,235
Z
Zongmei Zhou
H 指数:31论文数:301被引数:3,144
Z
Zhouguang Hui
H 指数:31论文数:296被引数:3,364
J
Jianyang Wang
H 指数:22论文数:154被引数:1,495
J
Jun Liang
H 指数:29论文数:281被引数:2,891
M
Moon J. Kim
H 指数:78论文数:443被引数:2.3万
Q
Qinfu Feng
H 指数:26论文数:247被引数:2,334
张
张海龙
H 指数:59论文数:437被引数:1.1万
D
Dongfu Chen
H 指数:24论文数:177被引数:1,702
J
Jima Lv
H 指数:22论文数:127被引数:1,586